CRISPR Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 407
- Market Cap
- -
- Website
- http://www.crisprtx.com
- Introduction
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
- Conditions
- Solid MalignancyHematologic Malignancy
- Interventions
- Other: Non Interventional
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 70
- Registration Number
- NCT06208878
- Locations
- πΊπΈ
Stanford, Stanford, California, United States
πΊπΈUT Southwestern, Dallas, Texas, United States
π¦πΊPeter MacCallum Cancer Center, Melbourne, Victoria, Australia
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
- Conditions
- Pancreatic AdenocarcinomaEsophageal CarcinomaClear Cell Renal Cell CarcinomaCervical CarcinomaMalignant Pleural Mesothelioma
- Interventions
- Biological: CTX131
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 250
- Registration Number
- NCT05795595
- Locations
- πΊπΈ
Research Site 2, Saint Louis, Missouri, United States
πΊπΈResearch Site 1, Nashville, Tennessee, United States
πΊπΈResearch Site 3, Duarte, California, United States
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Conditions
- B-cell LymphomaLarge B-cell LymphomaB-cell MalignancyMantle Cell LymphomaMarginal Zone LymphomaNon-Hodgkin LymphomaChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Follicular Lymphoma
- Interventions
- Biological: CTX112
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 120
- Registration Number
- NCT05643742
- Locations
- π¦πΊ
Research Site, Nedlands, Western Australia, Australia
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
- Conditions
- Diabetes MellitusMetabolic DiseaseImmune System DiseasesDiabetes Mellitus, Type 1Endocrine System DiseasesGlucose Metabolism DisordersAutoimmune Diseases
- Interventions
- Combination Product: VCTX211
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 40
- Registration Number
- NCT05565248
- Locations
- π¨π¦
University of Alberta, Edmonton, Alberta, Canada
π¨π¦University of British Columbia, Vancouver, British Columbia, Canada
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
- Conditions
- Metabolic DiseaseDiabetes Mellitus, Type 1Glucose Metabolism DisordersImmune System DiseasesAutoimmune DiseasesDiabetes MellitusEndocrine System Diseases
- Interventions
- Combination Product: VCTX210A unit
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 7
- Registration Number
- NCT05210530
- Locations
- π¨π¦
University of Alberta, Edmonton, Alberta, Canada
π¨π¦University of British Columbia, Vancouver, British Columbia, Canada
π¨π¦LMC Manna, Toronto, Ontario, Canada
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 49
- Registration Number
- NCT04502446
- Locations
- πΊπΈ
Research Site 9, New York, New York, United States
πΊπΈResearch Site 1, Houston, Texas, United States
π¨π¦Research Site 7, Toronto, Ontario, Canada
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 19
- Registration Number
- NCT04438083
- Locations
- πΊπΈ
Research Site 2, Duarte, California, United States
π¦πΊResearch Site 1, Melbourne, Victoria, Australia
π³π±Research Site 7, Amsterdam, North Holland, Netherlands
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 26
- Registration Number
- NCT04244656
- Locations
- πΊπΈ
University of Pennsylvania, Philadelphia, Pennsylvania, United States
πΊπΈSarah Cannon Research Institute, Nashville, Tennessee, United States
π¦πΊPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
- Conditions
- Non-Hodgkin LymphomaB-cell LymphomaAdult B Cell ALLB-cell Malignancy
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- CRISPR Therapeutics AG
- Target Recruit Count
- 62
- Registration Number
- NCT04035434
- Locations
- πΊπΈ
University of Maryland, Baltimore, Maryland, United States
πΊπΈHarold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
π¦πΊRoyal Prince Alfred Hospital, Sydney, New South Wales, Australia